seeding the future of monoclonal antibodies bioproduction
Our vision is to develop and mass produce safer, efficient, and cheaper biosimilar monoclonal antibodies for biotherapy. We believe that the next generation of medicine should be efficient and affordable worldwide.
Plantibodies is a unique biotech company dedicated to the development and bioproduction of biosimilar monoclonal antibodies to cure life threatening diseases such as cancers, neurodegenerative diseases, and autoimmune diseases.
Situation: The number of patients who suffer from cancer, neurodegenerative diseases, and pathogenic infections is rising steadily. For example, in the USA over 1.7 million people are diagnosed with cancer each year, costing over $147 billion dollars (2017), and 5.4 million people are diagnosed with Alzheimers and Parkinsons globally (2016).
Biologics are complex drugs that cannot easily be synthesised using classical chemistry technologies, and that are usually produced by living organisms such as mammalian cells.
Bioproduction challenges: The current monoclonal antibodies bioproduction methods have therefore several problems such as:
- The high cost of treatments, exceeding $100K of treatment per patient per year
- Risks of transmission of pathogenic contaminants to patients
- An expensive and limited scale-up capacity
- Use of animals origin reagents
Solution: Plantibodies proposes to solve these problems by using the plants to produce monoclonal antibodies. This will reduce the initial capital investment and lower operational costs, while improving the quality and safety of antibodies.
Opportunity: Over the next years many existing patents will expire, creating new opportunities for the manufacture of biosimilar antibodies. An untapped market of 3.1 billion people exists in Latin America, Asia, and Africa that needs inexpensive immunotherapy
Products: Our plant-based antibody production platform will produce biosimilar monoclonal antibodies that will be licensed to big pharmas for clinical trials and distribution.
cheaper, safer, and more stable antibodies
At Plantibodies we combine the latest advances in (1) synthetic biology, (2) plant biology, and (3) molecular biology, to bioproduce antibodies from plants.
Thanks to our patented core technlogies, know how and expertise, our antibodies will be mass produced, vertebrate pathogen free, and more stable than our competitors’.
an agile biotech company embedded in Paris (France) dynamic ecosystem
Plantibodies HQ are based in Paris 5th district. Our team works in close collaboration with PSL University and Sorbonne University, and is a member of Medicen Paris Region as well as France Biotech networks. You can find our offices at Pépinière 27 (Paris 11th), and our lab and facilities at GreenLab (Paris 5th). Plantibodies is supported by BPI France and has received the DeepTech label.
We are currently working on R&D and preclinical studies of 3 biosimilars. For more information, please contact us.
Highly qualified and innovation driven
From France’s top research bioscience institutions as well as business schools, this team has coalesced around the vision and the talents of Bilal Mazhar of creating plant-based antibodies that urgently need to be released onto the market on a mass scale, especially in developing countries.
Pierre BAUËR, Co-founder -CEO
Broadly trained in science (Engineer, PhD) and business (MBA)
BILAL MAZHAR, co-founder -cso
Chief Scientific Officer (CSO) of Plantibodies as well as its visionary.
Jessica APULEI, Co-founder - CTO
PhD in neuroscience and pathology at College de France (2019).
Won KIM, co-founder -advisor
PHD and MBA, full-time professor at ESCE, Paris business school.